Ewing's sarcoma oncogene structure: a novel prognostic marker?
JA Fletcher
JCO Apr 1 1998: 1241–1243. [PDF]
Germ cell tumors: there is still plenty to learn
GJ Bosl
JCO Apr 1 1998: 1244–1247. [PDF]
	EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma [published erratum appears in J Clin Oncol 1998 Aug;16(8):2895]
	E de Alava, A Kawai, JH Healey, I Fligman, PA Meyers, AG Huvos, WL Gerald, SC Jhanwar, P Argani, CR Antonescu, FJ Pardo-Mindan, J Ginsberg, R Womer, ER Lawlor, J Wunder, I Andrulis, PH Sorensen, FG Barr, and M Ladanyi
	JCO Apr 1 1998: 1248–1255. [Abstract] [PDF]
	Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study
	KK Matthay, C Perez, RC Seeger, GM Brodeur, H Shimada, JB Atkinson, CT Black, R Gerbing, GM Haase, DO Stram, P Swift, and JN Lukens
	JCO Apr 1 1998: 1256–1264. [Abstract] [PDF]
	Spontaneous regression of localized neuroblastoma detected by mass screening
	K Yamamoto, R Hanada, A Kikuchi, M Ichikawa, T Aihara, E Oguma, T Moritani, Y Shimanuki, M Tanimura, and Y Hayashi
	JCO Apr 1 1998: 1265–1269. [Abstract] [PDF]
	Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group
	NA Heerema, HN Sather, MG Sensel, P Kraft, JB Nachman, PG Steinherz, BJ Lange, RS Hutchinson, GH Reaman, ME Trigg, DC Arthur, PS Gaynon, and FM Uckun
	JCO Apr 1 1998: 1270–1278. [Abstract] [PDF]
	Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse
	CV Fernandez, CA Stutzer, L MacWilliam, and C Fryer
	JCO Apr 1 1998: 1279–1286. [Abstract] [PDF]
	Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study
	CR Nichols, PJ Catalano, ED Crawford, NJ Vogelzang, LH Einhorn, and PJ Loehrer
	JCO Apr 1 1998: 1287–1293. [Abstract] [PDF]
	Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels
	RT Zon, C Nichols, and LH Einhorn
	JCO Apr 1 1998: 1294–1297. [Abstract] [PDF]
	Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome
	HW Herr, DF Bajorin, and HI Scher
	JCO Apr 1 1998: 1298–1301. [Abstract] [PDF]
	Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas
	BV Kallakury, CE Sheehan, RA Ambros, HA Fisher, RP Kaufman, Jr, PJ Muraca, and JS Ross
	JCO Apr 1 1998: 1302–1309. [Abstract] [PDF]
	Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099
	M Al-Sarraf, M LeBlanc, PG Giri, KK Fu, J Cooper, T Vuong, AA Forastiere, G Adams, WA Sakr, DE Schuller, and JF Ensley
	JCO Apr 1 1998: 1310–1317. [Abstract] [PDF]
	Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study
	TG Wendt, GG Grabenbauer, CM Rodel, HJ Thiel, H Aydin, R Rohloff, TP Wustrow, H Iro, C Popella, and A Schalhorn
	JCO Apr 1 1998: 1318–1324. [Abstract] [PDF]
	Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
	DM Shin, BS Glisson, FR Khuri, L Ginsberg, V Papadimitrakopoulou, JJ Lee, K Lawhorn, AM Gillenwater, KK Ang, GL Clayman, DL Callender, WK Hong, and SM Lippman
	JCO Apr 1 1998: 1325–1330. [Abstract] [PDF]
	Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial
	AD Colevas, PM Busse, CM Norris, M Fried, RB Tishler, M Poulin, RL Fabian, TJ Fitzgerald, A Dreyfuss, ES Peters, S Adak, R Costello, JJ Barton, and MR Posner
	JCO Apr 1 1998: 1331–1339. [Abstract] [PDF]
	neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group
	IL Andrulis, SB Bull, ME Blackstein, D Sutherland, C Mak, S Sidlofsky, KP Pritzker, RW Hartwick, W Hanna, L Lickley, R Wilkinson, A Qizilbash, U Ambus, M Lipa, H Weizel, A Katz, M Baida, S Mariz, G Stoik, P Dacamara, D Strongitharm, W Geddie, and D McCready
	JCO Apr 1 1998: 1340–1349. [Abstract] [PDF]
	Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer
	T Eisen, IE Smith, S Johnston, PA Ellis, J Prendiville, MT Seymour, G Walsh, and S Ashley
	JCO Apr 1 1998: 1350–1357. [Abstract] [PDF]
	Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group
	A Goldhirsch, AS Coates, M Colleoni, M Castiglione-Gertsch, and RD Gelber
	JCO Apr 1 1998: 1358–1362. [Abstract] [PDF]
	Early breast cancer: evaluation of the prognostic role of the site of the primary tumor
	R Zucali, L Mariani, E Marubini, R Kenda, L Lozza, F Rilke, and U Veronesi
	JCO Apr 1 1998: 1363–1366. [Abstract] [PDF]
	Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast
	MJ Silverstein, MD Lagios, S Martino, BS Lewinsky, PH Craig, PJ Beron, P Gamagami, and JR Waisman
	JCO Apr 1 1998: 1367–1373. [Abstract] [PDF]
	No long-term increase in cardiac-related mortality after breast- conserving surgery and radiation therapy using modern techniques
	AJ Nixon, J Manola, R Gelman, B Bornstein, A Abner, S Hetelekidis, A Recht, and JR Harris
	JCO Apr 1 1998: 1374–1379. [Abstract] [PDF]
	Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer
	C Lindley, S Vasa, WT Sawyer, and EP Winer
	JCO Apr 1 1998: 1380–1387. [Abstract] [PDF]
	Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party
	JP Sculier, M Paesmans, J Thiriaux, J Lecomte, G Bureau, V Giner, A Efremidis, JJ Lafitte, MC Berchier, CG Alexopoulos, C Zacharias, P Mommen, V Ninane, and J Klastersky
	JCO Apr 1 1998: 1388–1396. [Abstract] [PDF]
	Novel staging protocol for non-small-cell lung cancers according to MRP- 1/CD9 and KAI1/CD82 gene expression
	M Adachi, T Taki, T Konishi, CI Huang, M Higashiyama, and M Miyake
	JCO Apr 1 1998: 1397–1406. [Abstract] [PDF]
	Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer
	K Pantel, B Passlick, J Vogt, P Stosiek, M Angstwurm, R Seen-Hibler, K Haussinger, O Thetter, JR Izbicki, and G Riethmuller
	JCO Apr 1 1998: 1407–1413. [Abstract] [PDF]
	Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole
	C Gridelli, F Perrone, GP Ianniello, L Brancaccio, RV Iaffaioli, C Curcio, M D'Aprile, R Cioffi, S Cigolari, A Rossi, G Palazzolo, E Veltri, M Pergola, S De Placido, C Gallo, S Monfardini, and AR Bianco
	JCO Apr 1 1998: 1414–1419. [Abstract] [PDF]
	Costs of care associated with non-small-cell lung cancer in a commercially insured cohort
	BE Hillner, MK McDonald, CE Desch, TJ Smith, LT Penberthy, P Maddox, and SM Retchin
	JCO Apr 1 1998: 1420–1424. [Abstract] [PDF]
	Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group
	H Pehamberger, HP Soyer, A Steiner, R Kofler, M Binder, P Mischer, W Pachinger, J Aubock, P Fritsch, H Kerl, and K Wolff
	JCO Apr 1 1998: 1425–1429. [Abstract] [PDF]
	Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? [published erratum appears in J Clin Oncol 1998 Jun;16(6):2293]
	DS Hoon, T Okamoto, HJ Wang, R Elashoff, AJ Nizze, LJ Foshag, G Gammon, and DL Morton
	JCO Apr 1 1998: 1430–1437. [Abstract] [PDF]
	Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study
	P Reichardt, J Tilgner, P Hohenberger, and B Dorken
	JCO Apr 1 1998: 1438–1443. [Abstract] [PDF]
	Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team
	BJ Dezube, JH Von Roenn, J Holden-Wiltse, TW Cheung, SC Remick, TP Cooley, J Moore, JP Sommadossi, SL Shriver, CW Suckow, and PS Gill
	JCO Apr 1 1998: 1444–1449. [Abstract] [PDF]
	Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
	RL Schilsky, J Hohneker, MJ Ratain, L Janisch, L Smetzer, VS Lucas, SP Khor, R Diasio, DD Von Hoff, and HA Burris, 3rd
	JCO Apr 1 1998: 1450–1457. [Abstract] [PDF]
	Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies
	AF Ratliff, J Wilson, M Hum, M Marling-Cason, K Rose, N Winick, and BA Kamen
	JCO Apr 1 1998: 1458–1464. [Abstract] [PDF]
	Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma
	R Gorlick, R Metzger, KD Danenberg, D Salonga, JS Miles, GS Longo, J Fu, D Banerjee, D Klimstra, S Jhanwar, PV Danenberg, N Kemeny, and JR Bertino
	JCO Apr 1 1998: 1465–1469. [Abstract] [PDF]
	Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
	E Gamelin, M Boisdron-Celle, R Delva, C Regimbeau, PE Cailleux, C Alleaume, ML Maillet, MJ Goudier, M Sire, MC Person-Joly, M Maigre, P Maillart, R Fety, P Burtin, A Lortholary, Y Dumesnil, L Picon, J Geslin, P Gesta, E Danquechin- Dorval, F Larra, and J Robert
	JCO Apr 1 1998: 1470–1478. [Abstract] [PDF]
	Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
	HR Alexander, Jr, DL Bartlett, SK Libutti, DL Fraker, T Moser, and SA Rosenberg
	JCO Apr 1 1998: 1479–1489. [Abstract] [PDF]
	Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study
	M Degiuli, M Sasako, A Ponti, T Soldati, F Danese, and F Calvo
	JCO Apr 1 1998: 1490–1493. [Abstract] [PDF]
	Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
	PG Rose, N Fusco, L Fluellen, and M Rodriguez
	JCO Apr 1 1998: 1494–1497. [Abstract] [PDF]
	High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase
	EJ Dann, J Anastasi, and RA Larson
	JCO Apr 1 1998: 1498–1504. [Abstract] [PDF]
	Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies
	R Surtees, J Clelland, and I Hann
	JCO Apr 1 1998: 1505–1511. [Abstract] [PDF]
	Nucleolar organizer region counts predict complete remission, remission duration, and survival in adult acute myelogenous leukemia patients
	A Pich, L Chiusa, E Audisio, and F Marmont
	JCO Apr 1 1998: 1512–1518. [Abstract] [PDF]
	Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study
	K Laczika, M Novak, B Hilgarth, M Mitterbauer, G Mitterbauer, A Scheidel- Petrovic, C Scholten, R Thalhammer-Scherrer, S Brugger, F Keil, I Schwarzinger, OA Haas, K Lechner, and U Jaeger
	JCO Apr 1 1998: 1519–1525. [Abstract] [PDF]
	Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity
	R Kurzrock, Z Estrov, H Kantarjian, and M Talpaz
	JCO Apr 1 1998: 1526–1531. [Abstract] [PDF]
	Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients
	PL Zinzani, S Pileri, M Bendandi, M Buzzi, E Sabattini, S Ascani, F Gherlinzoni, M Magagnoli, P Albertini, and S Tura
	JCO Apr 1 1998: 1532–1537. [Abstract] [PDF]
	Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization
	R Arranz, P Garcia-Alfonso, P Sobrino, P Zamora, R Carrion, J Garcia-Larana, G Perez, J Lopez, E Lavilla, M Lozano, C Rayon, R Colomer, MG Baron, E Flores, G Perez-Manga, and JM Fernandez-Ranada
	JCO Apr 1 1998: 1538–1546. [Abstract] [PDF]
	Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma
	KR Desikan, B Barlogie, S Jagannath, DH Vesole, D Siegel, A Fassas, N Munshi, S Singhal, J Mehta, S Tindle, J Nelson, D Bracy, S Mattox, and G Tricot
	JCO Apr 1 1998: 1547–1553. [Abstract] [PDF]
	Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization
	MJ Watts, AM Sullivan, D Leverett, AJ Peniket, AR Perry, CD Williams, S Devereux, AH Goldstone, and DC Linch
	JCO Apr 1 1998: 1554–1560. [Abstract] [PDF]
	High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?
	MJ Glantz, BF Cole, L Recht, W Akerley, P Mills, S Saris, F Hochberg, P Calabresi, and MJ Egorin
	JCO Apr 1 1998: 1561–1567. [Abstract] [PDF]
	Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
	RJ Gralla, RM Navari, PJ Hesketh, W Popovic, J Strupp, J Noy, L Einhorn, D Ettinger, W Bushnell, and C Friedman
	JCO Apr 1 1998: 1568–1573. [Abstract] [PDF]
	Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial
	AN Serafini, SJ Houston, I Resche, DP Quick, FM Grund, PJ Ell, A Bertrand, FR Ahmann, E Orihuela, RH Reid, RA Lerski, BD Collier, JH McKillop, GL Purnell, AP Pecking, FD Thomas, and KA Harrison
	JCO Apr 1 1998: 1574–1581. [Abstract] [PDF]
	Comorbidity and functional status are independent in older cancer patients
	M Extermann, J Overcash, GH Lyman, J Parr, and L Balducci
	JCO Apr 1 1998: 1582–1587. [Abstract] [PDF]
	Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine
	R Payne, SD Mathias, DJ Pasta, LA Wanke, R Williams, and R Mahmoud
	JCO Apr 1 1998: 1588–1593. [Abstract] [PDF]
	Oncologists' recognition of depression in their patients with cancer
	SD Passik, W Dugan, MV McDonald, B Rosenfeld, DE Theobald, and S Edgerton
	JCO Apr 1 1998: 1594–1600. [Abstract] [PDF]
	Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder
	MA Dimopoulos and LA Moulopoulos
	JCO Apr 1 1998: 1601–1612. [Abstract] [PDF]
	Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline
	DA Loblaw and NJ Laperriere
	JCO Apr 1 1998: 1613–1624. [Abstract] [PDF]
Case one. Bleomycin cutaneous toxicity
N Mullai, N Khokha, and G Shiomoto
JCO Apr 1 1998: 1625. [PDF]
Case two. Bleomycin cutaneous toxicity
W Yeo and PJ Johnson
JCO Apr 1 1998: 1626–1627. [PDF]
	Access to quality cancer care: consensus statement. American Federation of Clinical Oncologic Societies [published erratum appears in J Clin Oncol 1998 May;16(5):2001]
	JCO Apr 1 1998: 1628–1630. [Abstract] [PDF]
Concurrent is the key: combined modality small-cell lung cancer
RB Livingston
JCO Apr 1 1998: 1631a. [PDF]
Don't be mis-guided when the data are silent and the editorial misses the mark
CR Thomas, Jr, TE Williams, and AT Turrisi, 3rd
JCO Apr 1 1998: 1631b–1632. [PDF]
Timing of thoracic irradiation for limited small-cell lung cancer
N Murray
JCO Apr 1 1998: 1633–1635. [PDF]
Peripheral T-cell lymphoma after anti-CD20 antibody therapy [published erratum appears in J Clin Oncol 1998 May;16(5):2001]
S Tetreault, SL Abler, B Robbins, and A Saven
JCO Apr 1 1998: 1635–1637. [PDF]
Ethics of off-label treatment
CD Atkins
JCO Apr 1 1998: 1637. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.